ACMT/ASAM/ORN Addiction Toxicology Case Conference

Date & Time: Friday, September 4, 2020, 1:00 pm Eastern Time (New York)

Agenda:

1:00 – 1:05 PM  
**Introductions**

1:05 – 1:20 PM  
**Case 1: Preliminary Positive but Confirmation Negative — Suspected Designer Benzodiazepine Use in a Patient Maintained on SC Buprenorphine**

This case features a patient with combined opioid and sedative use disorder who has stabilized on buprenorphine without opioid use for years but has continued to use benzodiazepines and other sedatives. With increasing availability of "pressed 'Xanax'”, which include various synthetic benzodiazepines ordered from overseas through the internet, he has had ready access to illicit benzodiazepine supply. Additionally, he did much better in person compared to use of virtual meetings and phone/telemedicine counseling, often missing sessions or having “connection' problems”.

1:20 – 1:35 PM  
**Case 2: An Inexpensive, Potent, and Intense Intoxication — The Resurgence of K2 Use During the COVID-19 Pandemic**

A 44-year-old F is found acting bizarre and agitated. She has psychomotor agitation and bizarre 'rocking' movements and is markedly tachycardic and sweating profusely. She is on probation and has numerous legal issues related to substance use. Her parents believe she has been using various prescription medications inappropriately and is, "back on K2."

1:35 – 1:50 PM  
**Case 3: Extremely Restless, Diaphoretic and Yawning Repeatedly - Precipitated Withdrawal 48 hours After Last Fentanyl Use**

This case involves discussion of the different types of synthetic opioids found in the heroin supply and differences in pharmacology that would, in particular, impact the ability to start buprenorphine. Novel induction strategies are discussed, as are the mechanisms behind why patients seem
to be having more episodes of precipitated withdrawal and hesitancy in many instances in starting buprenorphine (or in restarting after 'holidays' of use).

1:50 – 2:00 PM Q&A w/ Audience

Moderators:

**Timothy J. Wiegand, MD FACMT** (ACMT/ASAM Expert)
Director of Toxicology and of the Toxicology Consult Service, University of Rochester Medical Center, Rochester, NY

**Gloria J. Baciewicz, MD** (ASAM Expert)
Medical Director, Strong Recovery; Professor of Clinical Psychiatry, Department of Psychiatry, University of Rochester Medical Center, Rochester, NY

Panelists:

**Michael Hodgman, MD** (ACMT Expert)
Assistant Professor of Emergency Medicine, Upstate Medical University, Syracuse, NY

**John A. Hopper, MD, DFASAM, FAAP, FACP** (ASAM Expert)
Clinical Professor, Wayne State University School of Medicine, Detroit, MI

**JoAn Laes, MD** (ACMT Expert)
Attending Physician, Division of Addiction Medicine, Hennepin County Medical Center, Minneapolis, MN

**Barry K. Logan, PhD, F-ABFT** (Guest Expert)
Executive Director, Center for Forensic Science Research and Education, Fredric Rieders Family Renaissance Foundation; Senior Vice President of Forensic Sciences, Chief Scientist, NMS Labs, Willow Grove, PA

**Learning Objectives. At the completion of the webinar participants will be able to:**

- Describe outcomes that lead to an improvement in response perspectives on navigating challenges that arise during novel care delivery.
- Explain methods to navigate challenges that arise utilizing telehealth and phone support.
- Identify related changes in monitoring for patients treated for opioid, alcohol, and other substance use disorders and in novel settings and using various types of telemedicine for support.
- Describe medication use and availability for patients treated for opioid, alcohol, and other substance use disorders and addiction in novel settings and using various types of contact for support.
AMA Credit Designation Statement:
The American Society of Addiction Medicine designates this internet live course for a maximum of
1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the
extent of their participation in the activity.

ACCME Accreditation Statement:
This activity has been planned and implemented in accordance with the essential areas and policies
of the Accreditation Council for Continuing Medical Education through the joint providership of The
American Society of Addiction Medicine and The American College of Medical Toxicology. The
American Society of Addiction Medicine is accredited by the ACCME to provide continuing medical
education for physicians.